Fiche centre
Minneapolis Clinic of Neurology
Burnsville — United States
Essais liés5clinical trials
VilleBurnsvillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06047444
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Dihydroergotamine | Migraine | Phase 3 | NCT03901482 | EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT04940390 | SUMMIT — A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine | COMPLETED |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047457 | E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults | ACTIVE_NOT_RECRUITING |
| Botulinum toxin type A | Migraine | Phase 3 | NCT06047444 | C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults | ACTIVE_NOT_RECRUITING |